In 2016, ExoDxTM Lung (ALK) became the first biomarker to successfully complete clinical trials, marking a milestone for EVs as disease diagnostic biomarkers by diagnosing lung cancer through the detection of EMLA-ALK mutations (Sheridan, 2016). This evidence concerns the gene ALK and lung cancer.